After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Strongbridge's deal with Novo Nordisk over Macrilen tops up the former's cash pile and pays off debt just 10 months after the company licensed the project from…
The big pharma’s cystic fibrosis deal with Galapagos is greeted with surprise, but the gamble might actually make sense.
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
A new partnership hunt awaits Geron Corporation as it seeks to defray the costs of the phase III imetelstat programme, making Ash presentations a key moment in the…